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doi:10.1016/j.jinf.2011.12.012Summary Objectives: This retrospective cohort study evaluated the risk of hepatotoxicity in
HIV-1 positive pregnant and non-pregnant women starting combined ART.
Methods: Data were used from the ATHENA observational cohort. The study population con-
sisted of HIV-1 infected, therapy na€ıve, pregnant and non-pregnant women, followed between
January 1997 and February 2008. Demographic, treatment and pregnancy related data were
collected. Risk of hepatotoxicity was determined using univariate and multivariate logistic re-
gression. Analyses were adjusted for age, region of origin, baseline HIV-RNA levels and CD4 cell
counts, cART regimen and hepatitis B and C coinfection. ALT and AST values of more than 5
times ULN were considered as hepatotoxicity.
Results: Four-hundred and twenty-five pregnant and 1121 non-pregnant women were in-
cluded. Independent risk factors of hepatotoxicity in all women were the presence of detect-
able HCV RNA (OR 5.48, 95% CI 2.25e13.38, p < 0.001) and NVP use (OR 2.63, 95% CI
1.54e4.55, p< 0.001). Stratified for pregnancy, the adjusted risk of hepatotoxicity was sig-
nificantly associated with HCV coinfection only during pregnancy (OR 23.53, 95% CI
4.69e118.01, p< 0.001). NVP use is related to hepatotoxicity in pregnant (OR 5.26, 95% CI
1.61e16.67, p < 0.005) as well as in non-pregnant women (OR 2.13, 95% CI 1.11e4.00,
pZ 0.02)., D418, Internal medicine, ’s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Tel.: þ31
musmc.nl (I.J.M. Snijdewind).
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Antiretroviral therapy (ART) is used world-wide to prevent
vertical transmission of HIV. In developing countries nevir-
apine (NVP) is the most frequently used drug to prevent
vertical transmission.1 During the last decade studies from
different regions in the world reported conflicting results
on the risk on mainly NVP-related liver toxicity in pregnant
women.1e10 One of the possible risk factors of hepatotoxic-
ity is a CD4þ cell count >250 cells/ml. Most studies reported
hepatotoxicity predominantly in women with CD4þ cell
counts >250/mm3.2e3,5,8 A recent retrospective study
from the UK found pregnancy to be significantly associated
with hepatotoxicity, without an association with NVP use or
CD4þ cell count.9
The HIV-1-positive ATHENA cohort in the Netherlands
comprises a multi-ethnic group of women from different
backgrounds with similar access to healthcare facilities.
The aim of our study was to examine the effects of
pregnancy, ethnicity, CD4þ cell count, hepatitis B (HBV)
or C (HCV) coinfection and combined ART (cART) on hepa-
totoxicity in women.
Patients and methods
Study design and setting
We conducted a retrospective cohort study among women
enrolled in the AIDS Therapy and Evaluation in The Nether-
lands (ATHENA)11 cohort study between January 1997 and
February 2008. Patients have provided written informed
consent for their data to be anonymously recorded in a cen-
tral database that is maintained by the HIV Monitoring
Foundation.11 The study was reviewed and approved by
the institutional review boards from all the involved
institutions.
Study population
We included all cART naive women from this cohort in their
reproductive phase of life (18e45 years), who started cART
between January 1997 and February 2008. The women were
first classified into two groups: pregnant or non-pregnant.
The pregnant group comprised women who started cART for
the first time, during pregnancy. We excluded pregnant
women who started cART before being pregnant. The non-
pregnant group included all women that started cART for
the first time, and were never pregnant during the
observational follow-up in the ATHENA cohort. cART was
defined as a regimen with two nucleoside reverse tran-
scriptase inhibitors (NRTIs) and either a third NRTI, a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or a pro-
tease inhibitor (PI). The duratrion of cART use was defined
as start date first line of therapy until second line therapy,
loss to follow-up date, date of death or date of closure ofthe dataset (February 2008). Women with high ALT or AST
values, three times the upper limit of normal (30 IU) at start
cART, were excluded from the study.
Data collection
Data were collected on demographics (age, region of
origin), clinical and treatment characteristics, side effects,
coinfection with HBV and HCV, Alanine-aminotransferase
(ALT), Aspartate-aminotransferase (AST), baseline CD4þ T-
cell counts and baseline HIV-RNA levels. Baseline was de-
fined as the start of cART. All women had routine check
ups with ALT and AST levels being monitored in weeks 2,
4, 12 after start of cART and during a clinical visit every 3
months hereafter and just before the predicted date of
birth. cART initiation date, duration and composition of
the regimens were retrieved. The occurrence of hepatotox-
icity is systemically collected and validated in the ATHENA
database.
Outcomes and study definitions
The outcome of interest was the occurrence of hepatotox-
icity in pregnant compared to non-pregnant women. The
observational period for side effects was 40 weeks after
start cART, as this is the mean duration of pregnancy.
Hepatotoxicity was defined in accordance with the AIDS
Clinical Trial Group criteria12 as grade 3 when ALT or AST
values were 5e10 (150e300 IU) times the upper limit of
normal (ULN), and as grade 4 when ALT or AST were >10
times ULN (>300 IU). Patients were considered to have
chronic HBV infection when HBsAg could be detected and
chronic HCV when HCV antibodies and HCV RNA were pres-
ent at start cART.
Statistical analyses
Statistical analyses were performed using the SPSS statis-
tical package PASW (version 17.0.2, IL, USA). Three differ-
ent tests were used to compare Baseline characteristics at
the start of cART initiation between non-pregnant and
pregnant women. ManneWhitney test was used to compare
medians of age, CD4þcell levels and HIV-RNA levels at start
cART. Chi-square test was used to compare regions of ori-
gin, coinfections with HBV and HCV. In case of small num-
bers the Fisher’s exact test was used to compare
differences in outcome between non-pregnant and preg-
nant women. Using univariate and multivariate logistic re-
gression analyses we evaluated risk factors for
hepatotoxicity. Risk factors accounted for were age, cART
regimen, region of origin, baseline HIV-RNA level, baseline
CD4þ T-cell levels, coinfection with HBV and with HCV. Fur-
ther analyses were stratified by regimen and pregnancy sta-
tus. Variables with a p-value <0.20 in the univariate
analyses were included in the multivariable logistic regres-
sion model.
cART in pregnant and non-pregnant women 411Results
Between 1997 and 2008, a total of 1924 HIV-1-positive
treatment naive women initiated cART. Women were
included from the first HIV positive test, and indexed at
the time of first cART use. Of these women, 768 became
pregnant at least once during follow-up. Only one preg-
nancy during cART use (the first) was included in the
study. Of the women who became pregnant, 125 were
already on cART before the start of pregnancy, 23 women
started cART after delivery, and 135 women had an
induced abortion or miscarriage in the first 16 weeks of
the pregnancy. The remaining 485 pregnant women
initiated cART during their pregnancy, 462 out of 485
women used cART for more than one week. Thirty-seven
women used mono or dual therapy and were excluded. In
total, 425 pregnant women, initiating cART with a minimal
duration of 7 days, could be included in the study. Of the
1156 women who did not become pregnant during the
observational period, 1121 started cART and continued
using it for at least one week. Thirty-five women were
excluded, due to less then 7 days usage of cART (nZ 34)
or monotherapy (nZ 1). None of the pregnant women
died during follow-up. In the non-pregnant group eight
women died, three deaths were AIDS related, three
deaths were non-AIDS related and in two cases the cause
of death was unknown.
Baseline characteristics
Baseline demographic, laboratory and treatment charac-
teristics are shown in Table 1. Pregnant women were
younger (28 versus 33 years, p-value< 0.001), originated
more often from Sub-Sahara Africa (SSA) (59% versus
50%, p-valueZ 0.006), had higher median CD4þ cell
counts (0.37 versus 0.18, p-value< 0.001) and lower HIV-
RNA levels (p-value< 0.0001). Asian women were equally
balanced among pregnant (nZ 25; 5.2%) and non-
pregnant (nZ 77; 6.7%) women. Pregnant women were
more often treated with a protease inhibitor (PI) based
regimen (74.8%) compared to non-pregnant women
(42.0%). In pregnant women 305/425 (71.8%) started
cART with a CD4þ cell count >250 ml, as opposed to 303/
1121 (27.0%) in the non-pregnant women. The median du-
ration of cART use in pregnancy was 15.9 weeks (IQR:
9.9e20.8). The median duration of the firstline cART reg-
imen in non-pregnant women was 31.4 weeks (IQR:
9.6e85.4). The majority of women (>90%) were infected
heterosexually.
Hepatotoxicity in women overall
In all women a total of 77 cases (5.0%) of grade 3 or 4
hepatotoxicity were reported (Table 1). Independent risk
factors of hepatotoxicity in all women were the presence
of detectable HCV RNA (OR 5.48, 95% CI 2.25e13.38,
p< 0.001) and NVP use (OR 2.63, 95% CI 1.54e4.55,
p< 0.001) (Table 2). The rate of hepatotoxicity was lower
in pregnant (nZ 16, 3.8%) compared to non-pregnant
(nZ 61, 5.4%) women. After adjustment for region of ori-
gin, hepatitis B and C coinfection, cART regimen, age atstart cART, HIV-RNA level and CD4þ cell count at base
line, the risk of hepatotoxicity did not differ between preg-
nant and non-pregnant women (OR 0.70, 95% CI 0.38e1.28,
pZ 0.25).
When analyses among all women were stratified by cART
regimen, HCV coinfection remained an independent signif-
icant risk factor for hepatotoxicity in efavirenz and PI-using
women only (OR 5.23, 95% CI 1.88e14.57, pZ 0.002) (data
not shown).
Hepatotoxicity in pregnant and non-pregnant
women
When the analysis was stratified by pregnancy, similar risk
factors were identified (Table 3). In pregnant women de-
tectable HCV-RNA and a NVP based regimen were both in-
dependently associated with a significantly higher risk of
hepatotoxicity (OR 23.53, 95% CI 4.69e118.01, p< 0.001
and OR 5.26, 95% CI 1.61e16.67, pZ 0.005), while in non-
pregnant women HCV coinfection was not found to be a sig-
nificant risk factor. Separate analysis of cART in non-
pregnant women demonstrated a moderate increased risk
of hepatotoxicity for NVP compared to PI use (OR 2.13,
95% CI 1.11-4.00, pZ 0.02). The median time from cART
initiation to grade 3 or 4 increase in ALT/AST levels was
7.56 (0.57e39.29) weeks in non-pregnant and 4.57
(0.14e17.00) weeks in pregnant woman, not a significant
difference (pZ 0.17).
We did a sensitivity analyses by excluding HCV coin-
fected women. In this analysis NNRTI use remained a signif-
icant risk factor for the occurrence of hepatotoxicity after
treatment initiation.
Finally, NVP induced hepatotoxicity resulted in discon-
tinuation of NVP in 89% (nZ14) and 43% (nZ26) in pregnant
and non-pregnant women respectively.
Discussion
In this study we analysed the occurrence of hepatotoxicity
after the start of cART in a group of HIV-1 infected
pregnant and non-pregnant women. Overall we observed
5.0% hepatotoxicity within 40 weeks after the start of
cART in all women. This rate did not differ between
pregnant and non-pregnant women. The risk of hepato-
toxicity in pregnant women was strongly associated with
the presence of HCV-RNA. NVP was associated with an
increased risk of hepatotoxicity in pregnant and non-
pregnant women.
Hepatotoxicity
The occurrence of 5% hepatotoxicity is in agreement with
proportions reported in several other studies ranging from
1.2 to 9%.1e4,6,8,9 Only one study, performed in Asian pa-
tients, reported a substantially higher rate of hepatotoxic-
ity (15.6%) in pregnant women using NVP.7 This study
however had only a small proportion of patients tested
for HBV or HCV, and the presence of a coinfection in this
study may have added to the high percentage of hepatotox-
icity, as HIV-positive Asian communities were found to have
a high prevalence of HCV.13
Table 1 Demographic and clinical characteristics of pregnant and non-pregnant women initiating cART.
Total 1546 Non-pregnant women
nZ 1121 (%)
Pregnant women,
nZ 425
P-value
Age at start cART
Median (IQR) 32 (26.7e36.7) 33 (28.3e38.1) 28 (23.6-32.0) <0.0001
Origin
NL, W Europe 300 (19.4) 232 (20.7) 68 (16) 0.006
SSA 805 (52.1) 556 (49.6) 249 (58.6)
Other 441 (28.5) 333 (29.7) 108 (25.4)
CD4 at start <0.0001
Median (IQR) 220 (119e360) 180 (70e275) 370 (232e530)
Missing 176 165 11
RNA level at start
Median 3.7 10 log 4 7.8 10 log 4 6.4 10 log 3 <0.0001
(Range) (17e2.1 10 log 8) (17e2.1 10 log 8) (25e7.5 10 log 5)
Missing 240 233 7
HBV coinfection
Yes 76 (4.9) 55 (4.9) 21 (4.9) 0.25
No 1355 (87.6) 975 (87.0) 380 (89.4)
Missing 115 (7.4) 91 (8.1) 24 (5.6)
HCV coinfection
ABþ 1154 (74.6) 814 (72.6) 340 (80.0) <0.001
ABþ and RNAþ 34 (2.2) 23 (2.1) 11 (2.6)
ABþ and RNA- 3 (0.2) 1 (0.1) 2 (0.5)
Missing AB or RNA 355 (23.0) 283 (25.2) 72 (16.9)
cART regime
NNRTI-based 685 (44.3) 582 (51.9) 103 (24.2) <0.0001
Nevirapine 359 257 102
Efavirenz 326 325 1
PI-based 789 (51.0) 471 (42.0) 318 (74.8)
Nelfinavir 403 136 267
Lopinavir 224 199 25
Saquinavir/R 58 39 19
Indinavir 34 29 5
Others 70 68 2
Both 27 (1.7) 23 (2.1) 4 (0.9)
Triple NRTI only 45 (2.9) 45 (4.0)
Hepatotoxicity
N (%) 77 (5.0) 61 (5.4) 16 (3.8) 0.18
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independent risk factor for antiretroviral-associated hepa-
totoxicity, including NVP-related hepatotoxicity.14 First,
there could be enhanced toxicity of pre-existing HCV- or
HBV-coinfection. Secondly, cART may be associated with
recovery of cell-mediated immunity, leading to immune-
mediated HBV- and HCV-specific liver cell damage and
transaminase elevation.15 This is supported by a review of
cohort studies, investigating the incidence of hepatotoxic-
ity among patients receiving cART, that failed to identify
a consistent association between a particular drug or drug
class and the development of subsequent hepatotoxicity.14
Most studies among asymptomatic pregnant and non-
pregnant women lack data on hepatitis coinfection. In
The Netherlands, HBV and HCV serology is routinelyassessed in HIV-positive patients, irrespective of liver en-
zymes or pregnancy. In our large cohort only 19.4% and
23.0% of women had missing data on coinfection, which en-
abled us to demonstrate the impact of a coinfection on
cART or pregnancy-induced hepatotoxicity.
NVP is significantly associated with an increased risk of
hepatotoxicity (OR 5.26, 95% CI 1.61e16.67, pZ 0.005) in
pregnant women and less evident in non-pregnant women
(OR 2.13. 95% CI 1.11e4.00, pZ 0.02). This has been re-
ported before3,8 and may be due to pregnancy related phys-
iological effects: changing pharmacokinetics by altered
activity of CYP2D6 and CYP3A4.16
Coinfection with HCV increases the risk of hepatotox-
icity in pregnant women (23.53 (4.69e118.01; p< 0.001).
Pregnancy has been shown to be an independent risk
Table 2 Risk factors for hepatotoxicity, analysis for all women.
n Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value
All women
Non pregnant 1121 1 1
Pregnant 425 0.68 (0.39e1.19) 0.18 0.70 (0.38e1.28) 0.25
Age quartiles
<27 406 1
27e32 399 0.91 (0.46e1.77) 0.77
32e37 371 1.35 (0.72e2.51) 0.35
>37 370 1.04 (0.54e2.02) 0.90
Origin
NL, W Europe 300 1
SSA 805 1.10 (0.59e2.04) 0.77
Other 441 1.07 (0.54e2.13) 0.84
CD4
<200 592 1
200e350 414 0.78 (0.42e1.42) 0.41
350e500 184 1.04 (0.50e2.16) 0.92
>500 180 0.95 (0.45e2.04) 0.90
Missing 176 1.09 (0.52e2.27) 0.82
HIV-RNA
Undetectable 118 1
Detectable 1188 1.14 (0.45e2.90) 0.79
Missing 240 1.51 (0.53e4.25) 0.44
HBV
Negative 1355 1
Positive 76 1.31 (0.51e3.36) 0.57
Missing data 115 0.50 (0.16e1.61) 0.25
HCV
AB 1154 1 1
ABþ, RNAþ 34 4.81 (2.01e11.50) <0.001 5.48 (2.25e13.38) <0.001
ABþ, RNA- 3 NA e NA e
Missing 355 0.59 (0.31e1.14) 0.12 0.59 (0.311.14) 0.12
Medication
NVP 359 1 1
EFV 326 0.64 (0.35e1.17) 0.14 0.57 (0.31e1.07) 0.08
PI 789 0.37 (0.22e0.64) 0.001 0.38 (0.22e0.65) <0.001
Both NNRTI/PI 27 0.88 (0.20e3.89) 0.99 0.86 (0.19e3.83) 0.84
NO NNRTI/PI 45 0.25 (0.03e1.87) 0.24 0.22 (0.03e1.66) 0.14
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Pregnancy is also associated with immune suppression,
and therefore may be responsible for susceptibility and
poor outcome of infectious diseases. Pregnant women
with hepatitis E developed fulminant hepatic failure
more frequently with mortality rates over 20%.17 This
may add to the argument of testing for HCV in HIV preg-
nant women, especially when a NVP-based regimen is
considered.
The strength of our study lies in the elaborate and
detailed baseline demographic and clinical data recorded
from a well-characterized population in the ATHENAcohort. Women from all social, ethnic and economic
backgrounds have the same access to health care in the
Netherlands. Therefore, selection bias was not likely to
occur.
Nonetheless our data have several limitations. Our study
is limited by its observational design. The data were
recorded by individual hospital data collectors and were
restricted to protocol. Furthermore, additional details on
the clinical severity of hepatotoxicity were not obtainable.
Occasionally data on CD4þ cell counts and liver enzymes
were lacking. Data on alcohol consumption were not
available.
Table 3 Risk factors for hepatotoxicity, analysis for pregnant and non-pregnant women.
Pregnant women Non-pregnant women
n Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value n Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value
Age quartiles
<27 189 1 1 217 1 1
27e32 129 2.65 (0.76e9.26) 0.13 2.47 (0.65e9.38) 0.18 270 0.52 (0.23e1.18) 0.12 0.51 (0.22e1.17) 0.11
32e37 79 1.83 (0.40e8.35) 0.44 1.43 (0.26e7.78) 0.68 292 0.99 (0.50e1.98) 0.98 1.03 (0.51e2.08) 0.94
>37 28 3.56 (0.62e20.40) 0.15 4.72 (0.59e37.82) 0.14 342 0.66 (0.32e1.37) 0.26 0.63 (0.30e1.32) 0.22
Origin
NL, W Europe 68 1 232 1
SSA 249 0.91 (0.24e3.39) 0.88 556 1.19 (0.59e2.40) 0.64
Other 108 0.62 (0.12e3.16) 0.56 333 1.22 (0.57e2.61) 0.62
CD4
<200 73 1 519 1
200e350 113 0.42 (0.07e2.58) 0.35 301 0.92 (0.48e1.75) 0.80
350e500 102 1.46 (0.35e6.03) 0.60 82 0.90 (0.31e2.63) 0.85
>500 126 0.96 (0.22e4.16) 0.96 54 1.40 (0.47e4.16) 0.54
Missing 11 NA e 165 1.13 (0.54e2.38) 0.75
HIV-RNA
Detectable 74 1 1 44 1
Undetectable 344 1.41 (0.31e6.40) 0.65 1.66 (0.33e8.35) 0.54 844 0.75 (0.22e2.52) 0.64
Missing 7 6.00 (0.47e76.14) 0.17 5.98 (0.34e103.94) 0.22 233 0.87 (0.24e3.18) 0.84
HBV
ABþ 380 1 1 975 1 1
AB 21 2.97 (0.63e14.12) 0.17 3.73 (0.63e21.94) 0.15 55 0.95 (0.29e3.13) 0.93 1.09 (0.33e3.66) 0.89
Missing data 24 1.23 (0.15e9.80) 0.81 1.24 (0.12e12.35) 0.86 91 0.37 (0.09e1.54) 0.17 0.79 (017e3.63) 0.76
HCV
AB 340 1 814 1 1
ABþ, RNAþ 11 27.18 (6.45e114.57) <0.001 23.53 (4.69e118.01) <0.001 23 2.20 (0.63e7.64) 0.22 2.56 (0.72e9.17) 0.15
ABþ, RNA 2 NA e e e 1 NA e NA
AB missing 72 3.55 (1.09e11.52) 0.035 3.09 (0.82e11.72) 0.10 283 0.32 (0.14e0.75) 0.009 0.34 (0.14e.86) 0.02
Medication
NVP 102 1 1 257 1 1
EFV 1 NA NA 325 0.47 (0.25e0.90) 0.02 0.47 (0.25e0.90) 0.02
PI 318 0.23 (0.08e0.64) 0.005 0.19 (0.06e0.62) 0.005 471 1.07 (0.24e4.88) 0.93 1.09 (0.23e5.06) 0.91
Both NNRTI/PI 4 NA NA 23 0.26 (0.03e1.95) 0.19 0.27 (0.04e2.09) 0.21
NO NNRTI/PI 45 0.66 (0.34e1.27) 0.21 0.63 (0.33e1.22) 0.17
NNRTI, non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; EFV, efavirenz /R Z boosted ritonavir; NL, The Netherlands; W Europe, western Europe;
SSA, sub-Saharan Africa Detectable: >500 HIV copies; Undetectable: <500 HIV copies; CD4, CD4þ T-cells; HCV, hepatitis C virus; AB, antibody; RNA, HCV-RNA; HBV, hepatitis B; OR, odds
ratio; NA, not applicable.
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HCV coinfection is strongly associated with hepatotoxicity
in pregnant HIV-infected women starting cART. NVP use
increased the risk of hepatotoxicity in pregnant as well as in
non-pregnant women. Hepatotoxicity was independent of
CD4þ cell count, region of origin, detectable HIV-RNA levels
and age.
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